Drugmakers Expected To Adopt Voluntary Restrictions On Direct-To-Consumer Advertising The pharmaceutical industry this week is expected to announce voluntary restrictions on direct-to-consumer drug advertising, the Wall Street Journal reports. The Pharmaceutical Research and Manufacturers Association will disclose restrictions that include suggesting drugmakers consider implementing a minimum time period before launching advertising for newly approved
drugs.
Source: www.medicalnewstoday.comPharma Package" Adopted - Particular Needs Of Non-Prescription Medicines Recognised The European Commission adopted today the so-called "pharma package", which consists of a Communication covering "a renewed vision for the pharmaceutical sector" and legislative proposals on information to patients, falsified
medicines and pharmacovigilance. "This package well recognises the particularities of non-
prescription medicines", stated AESGP (Association of the European Self-Medican Industry) Director General Hubertus Cranz.
Source: www.medicalnewstoday.comIMS Health Reports Annual Global Generics Prescription Sales Growth Of 3.6 Percent, To $78 Billion Global
prescription sales growth of generics
drugs slowed to 3.6 percent in the twelve months ending September 2008, down from 11.4 percent in 2007, according to a new report by IMS
Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and
healthcare industries.
Source: www.medicalnewstoday.comAlfacell's ONCONASE(R) And R-Amphinase Show Anti-Tumor Activity In Chronic Lymphocytic Leukemia And Acute Myeloblastic Leukemia Cells Alfacell Corporation (Nasdaq: ACEL) announced that American Society of Hematology (ASH) annual meeting abstracts in Blood (2008 112: Abstract 4205 & 2008 112: Abstract 4010) report that ONCONASE (ranpirnase) and R-Amphinase (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia (CLL)
Source: www.medicalnewstoday.comOncology Drug Iressa Better Than Chemotherapy In Some Patients, According To New Report From Cutting Edge Information Iressa's sales are poised to increase on positive clinical results suggesting that AstraZeneca's targeted lung cancer therapy performs better than standard chemotherapy in many patients, according to a new report, "Oncology Market Forecast to 2013", published by pharmaceutical business intelligence leader Cutting Edge Information.
Source: www.medicalnewstoday.comMany Drug Overdose Deaths Due To Non-Medical Use Of Prescription Pain Medication In an examination of unintentional overdose deaths in the state of West Virginia, a majority of these have been found to be associated with the nonmedical use and diversion of
prescription drugs, especially pain relievers, according to an article released on December 9, 2008 in JAMA.
Source: www.medicalnewstoday.comResistance To Use Of Generic Medications By Physicians 'Discouraging,' Editorial States "
Health care reformers have high hopes that the relentless rise in
prescription drug costs can be slowed by replacing brand-name
medicines with cheaper generic versions," but "so many physicians are so captive of the drug industry that it would take a huge effort to persuade more patients and doctors to use generics," a New York Times editorial states.
Source: www.medicalnewstoday.comStudy Showed New Episodes Of Depression Delayed In People Taking Cymbalta(R) .New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p
Source: www.medicalnewstoday.comSenior-Level Pharmaceuticals Executives Join Together To Debate Solutions To Fix Pharma's Failing Business Model On 2nd March 2009, some 40 senior-level pharmaceutical leaders will gather together in Barcelona Barcelona to discuss the drivers for change in pharma and how they can move and change quickly to sustain growth in these turbulent times. The event has been born out of the huge pressures pharma is facing right now: pricing pressures; increasing payor power and decreasing prescriber power; and the mounting stress on margins.
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 PM
